Pilot Project Renal and Cardiovascular Tertiary Prevention in Preeclampsia

NCT07151339 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital Schleswig-Holstein

Phase

Observational

Started

2024-11-01

Last updated

2025-09-03

Condition(s) studied

PreeclampsiaHELLP SyndromeEclampsiaKidney Disease

Study summary

Tertiary prevention program for women with preeclampsia, HELLP syndrome, kidney disease and pregnancy or associated conditions, including founding of a biobank. (Observational study since no interference with regular path of treatment suggested in national and international guidelines)

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * older than 18 yrs * diagnosed preeclampsia, HELLP syndrome or kidney disease durig pregnancy Exclusion Criteria: * unable for informed consent

Primary outcome measure(s)

Pulse wave velocity — 12 months

Trial sites (1)

Facility	City	Region	Status
University Hospital Schleswig- Holstein	Kiel	Germany	Recruiting

More University Hospital Schleswig-Holstein trials in Germany

Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact Recruiting

Dermatitis During Adjuvant Irradiation for BREAst Cancer: Recruiting

Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis Recruiting

Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease Starting soon

Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis Recruiting

Other trials for the same condition

Berlin-Brandenburg Pregnancy Cohort Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy Recruiting

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease Active, not recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation Recruiting

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07151339 on ClinicalTrials.gov ↗ ← All trials in Germany